GSK Reaches $2.2bn Deal to Buy Food Allergy Biotech RAPT

Why It Matters

The acquisition gives GSK a differentiated, long‑acting food‑allergy candidate, positioning it to capture a sizable U.S. market and diversify its immunology portfolio amid intensifying competition.

Key Takeaways

• GSK pays $2.2bn for RAPT Therapeutics.
• Ozureprubart targets food allergy IgE, Phase 2b now.
• Dosing every 12 weeks could outpace Xolair.
• Potential market: 17 million US patients, 1.3 million severe.
• Deal excludes mainland China, Macau, Taiwan, Hong Kong.

Pulse Analysis

GSK’s purchase of RAPT Therapeutics reflects a broader strategic shift under Luke Miels, who has prioritized accelerating pipeline development across oncology, respiratory and immunology assets. By adding ozureprubart, a next‑generation anti‑IgE antibody, GSK not only expands its immunology footprint but also signals confidence in biologics that address pediatric‑focused indications, a segment historically underserved by large‑molecule therapies. The move aligns with the company’s ambition to diversify revenue streams beyond vaccines and traditional small‑molecule drugs, reinforcing its position in a competitive biotech landscape.

Ozureprubart’s mechanism—targeting IgE to prevent allergic sensitisation—offers a compelling clinical profile. Unlike Xolair, which requires bi‑weekly to monthly injections, ozureprubart’s proposed 12‑week dosing could dramatically improve adherence, especially among children and their caregivers. The Phase 2b prestIgE trial results, expected in 2027, will be pivotal in confirming efficacy and safety, while a subsequent Phase 3 program aims to enroll both at‑risk adults and paediatric patients, a market of roughly 17 million in the United States alone. If successful, the drug could capture a share of the growing food‑allergy market, where current treatments are limited and biosimilar competition is emerging.

Beyond the immediate product, the acquisition bolsters GSK’s broader pipeline, granting access to RAPT’s CCR4 antagonist tivumecirnon, currently in Phase 2 for gastric cancer, and pre‑clinical programs targeting inflammatory diseases. This diversification mitigates reliance on a single asset and enhances GSK’s appeal to investors seeking robust growth prospects. Moreover, the deal underscores a wave of consolidation in pharma, where large firms acquire niche biotech innovators to accelerate time‑to‑market and fill therapeutic gaps. As GSK integrates RAPT’s assets, the company is poised to leverage its global commercialization capabilities, potentially reshaping the competitive dynamics of the food‑allergy and broader immunology markets.